- Home
- MVST vs INZY Comparison
MVST vs INZY Comparison
Compare MVST & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- INZY
- Stock Information
- Founded
- MVST 2006
- INZY 2015
- Country
- MVST United States
- INZY United States
- Employees
- MVST N/A
- INZY N/A
- Industry
- MVST Industrial Machinery/Components
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- MVST Miscellaneous
- INZY Health Care
- Exchange
- MVST Nasdaq
- INZY Nasdaq
- Market Cap
- MVST 182.8M
- INZY 188.2M
- IPO Year
- MVST N/A
- INZY 2020
- Fundamental
- Price
- MVST $2.03
- INZY $1.37
- Analyst Decision
- MVST Buy
- INZY Strong Buy
- Analyst Count
- MVST 3
- INZY 8
- Target Price
- MVST $3.33
- INZY $17.75
- AVG Volume (30 Days)
- MVST 20.5M
- INZY 677.5K
- Earning Date
- MVST 11-12-2024
- INZY 11-05-2024
- Dividend Yield
- MVST N/A
- INZY N/A
- EPS Growth
- MVST N/A
- INZY N/A
- EPS
- MVST N/A
- INZY N/A
- Revenue
- MVST $370,989,000.00
- INZY N/A
- Revenue This Year
- MVST $19.19
- INZY N/A
- Revenue Next Year
- MVST $29.35
- INZY N/A
- P/E Ratio
- MVST N/A
- INZY N/A
- Revenue Growth
- MVST 39.03
- INZY N/A
- 52 Week Low
- MVST $0.15
- INZY $1.38
- 52 Week High
- MVST $2.87
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- MVST 54.45
- INZY 20.23
- Support Level
- MVST $1.91
- INZY $2.68
- Resistance Level
- MVST $2.33
- INZY $3.18
- Average True Range (ATR)
- MVST 0.42
- INZY 0.28
- MACD
- MVST -0.07
- INZY -0.15
- Stochastic Oscillator
- MVST 19.52
- INZY 1.88
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.